Achieve Life Sciences (ACHV) Gains from Investment Securities (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Gains from Investment Securities of -$285000.0 in Q1 2026, down 350.0% on a QoQ basis from $114000.0 in Q4 2025, and down 413.19% year-over-year from $91000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Gains from Investment Securities across 17 years of filings, most recently posting -$285000.0 for Q1 2026.
- Quarterly Gains from Investment Securities fell 413.19% year-over-year to -$285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32000.0 (down 17.95% YoY) and the FY2025 annual result came in at $2.7 million, up 27.61% from the prior year.
- Gains from Investment Securities fell to -$285000.0 in Q1 2026, from $114000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $1.9 million in Q2 2024 and troughed at -$285000.0 in Q1 2026.
- A 5-year average of $401124.4 and a median of $190925.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities surged 396.26% — and 2026, when it sank 413.19%.
- Tracing ACHV's Gains from Investment Securities over 5 years: stood at -$47000.0 in 2022, then surged by 1460.64% to $639500.0 in 2023, then sank by 117.83% to -$114000.0 in 2024, then jumped by 200.0% to $114000.0 in 2025, then slumped by 350.0% to -$285000.0 in 2026.
- Business Quant data shows ACHV's Gains from Investment Securities at -$285000.0 in Q1 2026, $114000.0 in Q4 2025, and $106000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -285,000.00 |
| Mar 31, 2026 | -285,000.00 |
| Dec 31, 2025 | 114,000.00 |
| Dec 31, 2025 | 114,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Sep 30, 2025 | 106,000.00 |
| Jun 30, 2025 | 97,000.00 |
| Jun 30, 2025 | 97,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | -114,000.00 |
| Dec 31, 2024 | -114,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Sep 30, 2024 | 62,000.00 |
| Jun 30, 2024 | 1.93 Mn |
| Jun 30, 2024 | 1.93 Mn |
| Mar 31, 2024 | 466,500.00 |
| Mar 31, 2024 | 466,500.00 |
| Sep 30, 2023 | 639,500.00 |
| Sep 30, 2023 | 639,500.00 |